CloneID: SGN-33 (Lintuzumab)
Antigen Long Description: This humanized antibody was prepared by combining the CDR regions of the murine anti-CD33 M195 with human framework and constant regions.
Origin Pub PMID: 1737932
Buffer Composition: PBS only.
Chimeric Use Statement: NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
Uniprot Accession No.: P20138
Specificity Statement: This antibody is specific for human CD33, which is restricted to cells of the myelomonocytic lineage. CD33 but does not appear in abundance on normal cells, but is over-expressed in AML and other myeloproliferative diseases.
Application Notes (Clone): In vitro, this antibody is capable of mediating ADCC against AML cells (Caron, 1998). Though shown to be safe in phase III trials, the use of this antibody in combination with induction chemotherapy did not result in a statistically significant improvement in response rate or survival in patients with refractory/relapsed AML (Feldman, 2005).
English
Deutsch
